2026-01-21 - Analysis Report
**Report: Novo Nordisk (NVO)**

### Company Overview:
Novo Nordisk is a global healthcare company that develops and produces innovative pharmaceutical solutions and diabetes care products.

### Comparative Return Analysis

* Cumulative return of review stock (NVO): 49.25%
* Cumulative return of comparison stock (S&P 500, VOO): 89.37%
* Divergence: -40.00, Relative divergence: 19.40%

### Performance Analysis

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 0.0% | 19.0% | -5.0% | 0.8  | 102.4B |
| 2017-2019  | 37.0% | 13.6% | 20.0% | 0.6  | 128.6B |
| 2018-2020  | 1.0% | 12.5% | -20.0% | 0.6  | 155.2B |
| 2019-2021  | 58.0% | 13.0% | 15.0% | 0.6  | 248.8B |
| 2020-2022  | 58.0% | 23.2% | 60.0% | 0.6  | 300.7B |
| 2021-2023  | 87.0% | 23.2% | 86.0% | 0.5  | 459.7B |
| 2022-2024  | 18.0% | 40.5% | -1.0% | 0.5  | 382.2B |
| 2023-2025  | -52.0% | 59.7% | -114.0% | 0.7  | 226.1B |

### Stock Price Fluctuations

* Close: $60.68
* Last-market: {'price': 60.68, 'previousClose': 62.33, 'change': -2.65}
* 5-day SMA: $59.74
* 20-day SMA: $55.07
* 60-day SMA: $50.85

### Technical Indicators

* RSI: 74.02
* PPO: 0.89
* Market Risk Indicator (MRI): 0.80 (Neutral)
* Hybrid Signal: Buy (Cash 0%)

### Recent Events and News

* [2026-01-06] Novo Nordisk: NVO Stock To $100? - Forbes
* [2026-01-20] Lobbying Update: $2,120,000 of NOVO NORDISK INC. lobbying was just disclosed - Quiver Quantitative
* [2026-01-06] Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
* [2026-01-20] NVO Stock Today: January 20 Tariff Jitters Test Novo Nordisk Rally - Meyka
* [2026-01-20] ‘Sales and Earnings to Shrink in 2026’ TD Cowen Says of Novo Nordisk Stock (NVO) - TipRanks
* [2026-01-16] NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? - Stocktwits

### Analyst Opinions

* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
  - Opinions: 11
  - Target Price (avg/high/low): 56.36 / 73.95 / 41.93

### Comprehensive Analysis

Based on the analysis, Novo Nordisk (NVO) has shown a relatively stable cumulative return, but is lagging behind the S&P 500. The recent stock price fluctuations indicate a slight decline, with a 20-day SMA lower than the close. The technical indicators suggest a neutral market risk, with a hybrid signal to buy. However, the recent news has highlighted some concerns, such as tariff jitters and potential shrinkage in sales and earnings. The analyst consensus is generally positive, with a mean rating of Buy and a target price range of $56.36 to $73.95. Overall, the stock presents a moderate risk-reward profile, warranting a cautious approach.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.